Routine blood coagulation tests were performed on 431 consecutive patients enrolled in a
study of the role of anticoagulation in cancer treatment (VA Cooperative Study# 75). Two …

Abnormalities of the so called" routine" blood coagulation tests have been described in up to
90% of cancer patients. The most common abnormalities described are: elevation of clotting …

Coagulation tests including platelet count, factor V assay, fibrinogen, fibrin split products,
and serial thrombin time were performed on 51 patients with cancer. Elevated fibrin split …

As solid tumours rely upon the bloodstream to deliver nutrients necessary for growth, it
follows that interference with that supply may compromise tumour growth. Indeed, this …

A comprehensive study of the hemostatic and coagulation mechanisms in 50 patients with
disseminated malignancy was carried out. Significant laboratory abnormalities were found in …

Nearly all patients with cancer manifest laboratory evidence of hypercoagulability and some
develop clinical thromboembolic disease (TED). Routine laboratory studies of blood …

A prospective study of hemostatic abnormalities in 108 cancer patients was undertaken at
an oncology clinic in a university teaching hospital. Tests included Quick prothrombin time …

Fibrinopeptide A (FPA) levels have been followed sequentially in a three‐year study of 50
patients with advanced carcinoma. Evidence for activation of blood coagulation was found in …

Blood coagulation and platelet function was evaluated in 106 hospitalized patients with
cancer and compared with 40 patients with nonmalignant diseases and 50 normal subjects …

We performed coagulation profiles including a complete blood count (CBC), prothrombin
time (PT), activated partial thromboplastin time (aPTT), thrombin time (TT), and quantitation …